Alopecia androgenética masculina de inicio precoz asociada a cáncer de próstata
DOI:
https://doi.org/10.29166/ciencias_medicas.v42i2.1492Keywords:
Baldness, Androgenetic alopecia, Prostate cancer, Baldness pattern, SeverityAbstract
Context: male androgenetic alopecia is usual in men between 30 to 70 years of age; Its early presentation occurs in males under 31 years, related to androgens and inheritance, important factors in its etiopathogenesis. It has aesthetic repercussion, however, it is associated with cardiovascular risk and prostate cancer; It is postulated that the hormonal influence in male androgenetic alopecia favors the development of prostate cancer and determines its severity.
Objective: To determine the association between early male alopecia and prostate cancer.
Subjects and methods: men older than 18 years with confirmed prostate cancer; The control group consists of men older than 18 years without neoplasms with negative determination of prostate antigen. The study was carried out at the Carlos Andrade Marín HCAM Hospital, from May to September 2015.
Results: relationship between androgenetic alopecia before 31 years and prostate cancer, with an OR of 4.25 (95% CI 1.7-10, p = 0.001). No statistical difference was observed between the severity of the prostate cancer and the clinical alopecic pattern.
Conclusion: patients with early male androgenetic alopecia 31 years, have a higher risk of developing prostate cancer; Early androgenetic alopecia could be considered as an indicator of risk for prostate cancer, deserving its screening in patients with this early baldness.
Downloads
Metrics
References
Ellis J, Sinclair R, Harrap S. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 2002; 4:1.
Mulinari Brenner F, Seidel G, Hepp T. Entendiendo la alopecia androgenética. Surg Cosmet Dermatol 2011; 3(4):329-337.
Partin A, Rodriguez R. The molecular biology, endocrinology and physiology of the prostate and seminal vesicles en Kavoussi, Novick, Partin, Peters. Utología de Campbell. 8ed. Philadelphia:Saunders, 2002; pp 1237-1283.
Severi G, Morris H, Macinnis R, English D, Tilley W, Hopper J, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:86–91.
Hayes V, Severi G, Padilla E, Morris HA, Tilley W, Southey M, et al. 5a-reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia . Int J Cancer 2006; 120:776–780 .
Ellis J, Stebbing M, Harrap S. Genetic analysis of male pattern baldness and the 5a-reductase genes. J Invest Dermatol 1988; 110:849–53.
Marks L, Mazer N, Mostaghel E, Hess D, Dorey F, Epstein J, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296:2351–2361.
Yassa M, Saliou M, De Rycke Y, Hemery C, Henni M, Bachaud J, et al. Male pattern baldness and the risk of prostate cancer. Annals of Oncology 2011; 1:1-4.
Graham G, Severi G, Sinclair R, et al. Androgenetic alopecia and prostate cancer: findings from an australian case-control study . Cancer Epidemiol Biomarkers Prev 2002; 11:549-553.
Wang T, Zhou C, Shen Y, Wang X, Ding X, Tian S, et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol 2010; 162:843-847.
Gan D, Sinclair R. Prevalence of male and female pattern hair loss in Maryborough. J. Investig Dermatol Symp Proc 2005; 10:184-189.
Richards J, Yuan X, Geller F, et al. Male-pattern baldness susceptibility locus at 2011. Nat Genet 2008; 40:1282-284.
Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol 2010; 79:613-25.
Amoretti A, Laydner H, Bergfeld W. Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. J Am Acad Dermatol 2013; 68:937-943.
